Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Sahar Khan, Salman Basrai, Esther Masih-Khan, Harjot Vohra, Donna Reece, Suzanne Trudel, Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Aaron Schimmer, Sagi Abelson, Christine I Chen

Blood (2024) 144 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2024-210717

Published: 2024

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis

Aaron Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): SCI-11.

https://doi.org/10.1182/blood-2018-99-109470

Published: 2018

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML

Sara Mirali, Botham Aaron, Veronique Voisin, PhD, Yihua Qiu, Fieke W Hoff, BSc, Rose Hurren, BSc, Marcela Gronda, MSc, Yulia Jitkova, PhD, G. Wei Xu, Neil MacLean, Xiaoming Wang, Terzah M. Horton, MD PhD, Steven M. Kornblau, MD, Steven M Chan, MD PhD, Gary D Bader, Aaron Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2018-99-110869

Published: 2018

Journal Articles

Targeting the Mitochondrial Metallochaperone Cox17 Reduces DNA Methylation and Promotes AML Differentiation through a Copper Dependent Mechanism

Blood (2018) 132 (Supplement 1): 1339.

https://doi.org/10.1182/blood-2018-99-111015

Published: 2018

Journal Articles

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

Blood (2017) 130 (Supplement 1): 788.

https://doi.org/10.1182/blood.V130.Suppl_1.788.788

Published: 2017

Journal Articles

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Dina Khalaf, MD BSc, Steven M. Chan, MD PhD, Vikas Gupta, MD PhD, Andrzej Lutynski, MD, Dawn Maze, MD FRCPC, MSc, Mark D. Minden, MD PhD, Yoichiro Natori, MD, Rhea Pavan, BA, Amr Rostom, MD, Anna Rydlewski, MD, Aaron Schimmer, MD PhD, Andre Schuh, MD FRCPC, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Shahid Husain, MD MS

Blood (2017) 130 (Supplement 1): 4682.

https://doi.org/10.1182/blood.V130.Suppl_1.4682.4682

Published: 2017

Journal Articles

Migration in the Management of Philadelphia Positive ALL: Towards a Lower Risk of VTE

Hassan Sibai, MBBS, Maria Zigas, Arjun Datt Law, MBBS, MD DM, Umberto Falcone, MD, Solaf Sami Kanfar, MD, Naoko Sakurai, Vikas Gupta, MD PhD, Andre Schuh, MD FRCPC, Karen W.L. Yee, MD, Aaron Schimmer, MD PhD, Mark D. Minden, MD PhD, Dawn Maze, MD FRCPC, MSc, Steven M. Chan, MDPhD, Jack Seki, PharmD

Blood (2017) 130 (Supplement 1): 1283.

https://doi.org/10.1182/blood.V130.Suppl_1.1283.1283

Published: 2017

Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Blood (2013) 122 (21): 1548.

https://doi.org/10.1182/blood.V122.21.1548.1548

Published: 2013

Journal Articles

Targeting The Mitochondrial ClpP As a Novel Therapeutic Strategy For Acute Myeloid Leukemia

Alicia Cole, PhD, Zezhou Wang, PhD, Rachel Mattson, Etienne Coyaud, PhD, Rose Hurren, Marcela Gronda, MSc, Fengshu Lin, PhD, Neil Maclean, BSc, Elisa Leung, BSc, Yihua Qiu, MD, Nianxiang Zhang, PhD, Kevin R. Coombes, PhD, Mark D. Minden, MD PhD, Walid A. Houry, PhD, Zenyaho Hao, PhD, Steven M. Kornblau, MD, Brian Raught, PhD, Aaron Schimmer, PhD, MD

Blood (2013) 122 (21): 3937.

https://doi.org/10.1182/blood.V122.21.3937.3937

Published: 2013

Journal Articles

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Blood (2013) 122 (21): 1988.

https://doi.org/10.1182/blood.V122.21.1988.1988

Published: 2013

Journal Articles

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

G. Wei Xu, MD, PhD, Julia I. Toth, PhD, Sara R. da Silva, BSc, Stacey-Lynn Paiva, BSc, Julie L. Lukkarila, PhD, Rose Hurren, Neil Maclean, BSc, Mahadeo A. Sukhai, PhD, Rabindra N. Bhattacharjee, PhD, Carolyn A. Goard, PhD, Bruno C Medeiros, MD, Patrick T. Gunning, PhD, Sirano Dhe-Paganon, PhD, Matthew D. Petroski, PhD, Aaron Schimmer, PhD, MD

Blood (2013) 122 (21): 2527.

https://doi.org/10.1182/blood.V122.21.2527.2527

Published: 2013

Journal Articles

ODE-Adefovir As Potential Therapeutic Agent In AML

Haytham Khoury, MD, Hu Ruijuan, Aaron Schimmer, PhD, MD, Karl Hostetler, MD, Mark D Minden, MD, PhD

Blood (2013) 122 (21): 3970.

https://doi.org/10.1182/blood.V122.21.3970.3970

Published: 2013

Journal Articles

Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias

Polina Matre, PhD, Ismael Samudio, PhD, Rodrigo Jacamo, PhD, Ying Wang, Jing Wang, R Eric Davis, Xiaohua Su, Sonja Schindela, Rachel Newman, Jianhua Hu, Torsten Haferlach, MD, Michael Andreeff, MD, PhD, Elsa R. Flores, Aaron Schimmer, PhD, MD, Marina Konopleva, MD, PhD

Blood (2013) 122 (21): 606.

https://doi.org/10.1182/blood.V122.21.606.606

Published: 2013

Journal Articles

A Phase I Study Of Nilotinib As a c-Kit Inhibitor Combined With Re-Induction Chemotherapy For Relapsed and Refractory c-Kit Positive Acute Myeloid Leukemia

Joseph M. Brandwein, MD, David Hedley, MD, Sue Chow, Karen Yee, MD, Andre C Schuh, MD, Vikas Gupta, MD, FRCP, FRCPath, Aaron Schimmer, PhD, MD, Mark D. Minden, MD, PhD

Blood (2013) 122 (21): 3961.

https://doi.org/10.1182/blood.V122.21.3961.3961

Published: 2013

Journal Articles

Azacitidine Has Limited Activity in Patients with MDS and AML

Karen Yee, MD, Symron Bansal, Joseph Brandwein, MD, Mark D. Minden, MD, Aaron Schimmer, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, Arsenia Dharman, Christine Cserti-Gazdewich, MD, Andre Schuh, MD, FRCPC

Blood (2011) 118 (21): 5057.

https://doi.org/10.1182/blood.V118.21.5057.5057

Published: 2011

Journal Articles

A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia

Karen W.L. Yee, MD, Hsaio-Wei Tina Chen, Joseph Brandwein, MD, FRCPC, Sue Chow, Deborah Sanfelice, David Hedley, MD, Vikas Gupta, MD, MRCP, FRCPath, Aaron Schimmer, MD, PhD, Carolyn Fowler Sidor, MD, Graham Fletcher, Jamie Arnott, Mark Bray, Mark D. Minden, MD, PhD, Andre Schuh, MD, FRCPC

Blood (2010) 116 (21): 3307.

https://doi.org/10.1182/blood.V116.21.3307.3307

Published: 2010

Journal Articles

Clioquinol Arrests Cell Cycle at G1 Phase and Triggers Intrinsic Apoptosis In Myeloma and Leukemia Cells by Inhibiting Histone Deacetylases

Biyin Cao, Tingjun Hou, PhD, Suning Chen, Depei Wu, Aining Sun, Huiying Qiu, Wenjie Wang, Aaron Schimmer, MD, PhD, Xinliang Mao, MD, PhD

Blood (2010) 116 (21): 1836.

https://doi.org/10.1182/blood.V116.21.1836.1836

Published: 2010

Journal Articles

The Anti-Malarial Mefloquine Demonstrates Preclinical Activity In Leukemia and Myeloma, and Is Dependent Upon Toll-Like Receptor Signaling for Its Cytotoxicity

Mahadeo A. Sukhai, PhD, Xiaoming Li, PhD, Rose Hurren, Xiaoming Wang, Skrtic Marko, B.Sc., Hong Sun, Marcela Gronda, Ayesh Seneviratne, Dilan Dissanayake, Sue Chow, Rod Bremner, PhD, David Hedley, MD, Mark D. Minden, MD, PhD, Ohashi Pamela, PhD, FRSC, Aaron Schimmer, MD, PhD

Blood (2010) 116 (21): 290.

https://doi.org/10.1182/blood.V116.21.290.290

Published: 2010

Journal Articles

A Prognostic Score of Overall Survival In Adults with Acute Myeloid Leukemia

Murtadha K. Al-Khabori, MD, FRCPC, Gordon Guyatt, MD, FRCPC, Mark D. Minden, MD, PhD, Karen Yee, MD, Vikas Gupta, MD, MRCP, FRCPath, Aaron Schimmer, MD, PhD, Andre Schuh, MD, FRCPC, Joseph Brandwein, MD, FRCPC

Blood (2010) 116 (21): 2730.

https://doi.org/10.1182/blood.V116.21.2730.2730

Published: 2010

NARROW

Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML

Targeting the Mitochondrial Metallochaperone Cox17 Reduces DNA Methylation and Promotes AML Differentiation through a Copper Dependent Mechanism

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Migration in the Management of Philadelphia Positive ALL: Towards a Lower Risk of VTE

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Targeting The Mitochondrial ClpP As a Novel Therapeutic Strategy For Acute Myeloid Leukemia

FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

ODE-Adefovir As Potential Therapeutic Agent In AML

Unraveling The Molecular and Metabolic Basis For Glutamine Addiction In Leukemias

A Phase I Study Of Nilotinib As a c-Kit Inhibitor Combined With Re-Induction Chemotherapy For Relapsed and Refractory c-Kit Positive Acute Myeloid Leukemia

Azacitidine Has Limited Activity in Patients with MDS and AML

A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia

Clioquinol Arrests Cell Cycle at G1 Phase and Triggers Intrinsic Apoptosis In Myeloma and Leukemia Cells by Inhibiting Histone Deacetylases

The Anti-Malarial Mefloquine Demonstrates Preclinical Activity In Leukemia and Myeloma, and Is Dependent Upon Toll-Like Receptor Signaling for Its Cytotoxicity

A Prognostic Score of Overall Survival In Adults with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only